These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29438199)

  • 1. Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals.
    Mora-Peris B; Bouliotis G; Ranjababu K; Clarke A; Post FA; Nelson M; Burgess L; Tiraboschi J; Khoo S; Taylor S; Ashby D; Winston A
    AIDS; 2018 May; 32(8):1007-1015. PubMed ID: 29438199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
    Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
    Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
    Stellbrink HJ; Le Fevre E; Carr A; Saag MS; Mukwaya G; Nozza S; Valluri SR; Vourvahis M; Rinehart AR; McFadyen L; Fichtenbaum C; Clark A; Craig C; Fang AF; Heera J
    AIDS; 2016 May; 30(8):1229-38. PubMed ID: 26854810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
    Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D
    Ann Intern Med; 2020 Mar; 172(5):297-305. PubMed ID: 32040959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
    Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ
    AIDS; 2016 Feb; 30(4):591-600. PubMed ID: 26825032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
    Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
    J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognition with maraviroc compared with tenofovir in HIV.
    Robertson KR; Miyahara S; Lee A; Brown TT; Chan ES; Berzins B; Rusin D; Eron JJ; Taiwo BO;
    AIDS; 2016 Sep; 30(15):2315-21. PubMed ID: 27333088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
    Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA;
    HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
    Pressiat C; Hirt D; Treluyer JM; Zheng Y; Morlat P; Naqvi A; Tran L; Viard JP; Avettand-Fenoel V; Rouzioux C; Meyer L; Cheret A;
    J Antimicrob Chemother; 2018 Apr; 73(4):1020-1024. PubMed ID: 29365125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
    Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
    Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
    Saumoy M; Ordóñez-Llanos J; Martínez E; Ferrer E; Domingo P; Ribera E; Negredo E; Curto J; Sánchez-Quesada JL; Di Yacovo S; González-Cordón A; Podzamczer D
    J Antimicrob Chemother; 2015 Apr; 70(4):1130-8. PubMed ID: 25538166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
    Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
    Infez Med; 2015 Mar; 23(1):36-43. PubMed ID: 25819049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.